Inter-observer and Intra-observer Agreement in Pathological Evaluation of Non-alcoholic Fatty Liver Disease Suspected Liver Biopsies

Authors Information
Article Notes and Dates
To Cite : Pournik O, Alavian S M, Ghalichi L, Seifizarei B, Mehrnoush L, et al. Inter-observer and Intra-observer Agreement in Pathological Evaluation of Non-alcoholic Fatty Liver Disease Suspected Liver Biopsies, Hepat Mon. 2014 ;14(1):e15167. doi: 10.5812/hepatmon.15167.
Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable? Hepat Mon. 2012; 13(2)[DOI]
  • 2. Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Exp Rev Gastroentero Hepatol. 2011; 5(2): 223-231[DOI][PubMed]
  • 3. Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. J Dig Dis. 2009; 10(1): 7-14[DOI][PubMed]
  • 4. Scoazec JY. Liver biopsy: Which role in patient management? Ann De Pathol. 2010; 30(6): 464-469[DOI][PubMed]
  • 5. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011; 5(2): 625-634[DOI][PubMed]
  • 6. Yeshua H, Oren R. Non invasive assessment of liver fibrosis. Ann Transplant. 2008; 13(2): 5-11[PubMed]
  • 7. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2005; 128(7): 1898-1906[DOI]
  • 8. Bedossa P. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C. Hepatology. 1994; 20(1): 15-20[DOI]
  • 9. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996; 25(5): 649-654[DOI][PubMed]
  • 10. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005; 41(2): 257-264[DOI][PubMed]
  • 11. Woynarowski M, Cielecka-Kuszyk J, Kaluzynski A, Omulecka A, Sobaniec-Lotowska M, Stolarczyk J, et al. Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment. World J Gastroenterol. 2006; 12(11): 1713-1717[PubMed]
  • 12. Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol. 2011; 45(1): 55-58[DOI][PubMed]
  • 13. Robert M, Sofair AN, Thomas A, Bell B, Bialek S, Corless C, et al. A Comparison of Hepatopathologists' and Community Pathologists' Review of Liver Biopsy Specimens From Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2009; 7(3): 335-338[DOI][PubMed]
  • 14. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diag Pathol. 2011; 15(1): 19-24[DOI][PubMed]
  • 15. Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313-1321[DOI]
  • 16. Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, et al. Correlation of Vitamin E, Uric Acid, and Diet Composition With Histologic Features of Pediatric NAFLD. J Ped Gastroenterol Nut. 2012; 54(1): 90-96[DOI][PubMed]
  • 17. Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharm Therapeutics. 2011; 34(2): 214-218[DOI][PubMed]
  • 18. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009; 49(1): 306-317
  • 19. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012; 56(5): 1751-1759[DOI][PubMed]
  • 20. Fukusato T, Fukushima J, Shiga J, Takahashi Y, Nakano T, Maeyama S, et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res. 2005; 33(2): 122-127[DOI][PubMed]
  • 21. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38(6): 1449-1457[DOI]
  • 22. Bedossa P, Carrat F. Liver biopsy: The best, not the gold standard. J Hepatol. 2009; 50: 1-3
  • 23. Bejarano PA, Koehler A, Sherman KE. Second opinion pathology in liver biopsy interpretation. Am J Gastroenterol. 2001; 96(11): 3158-3164[DOI][PubMed]
  • 24. Aalaei-Andabili SH, Mehrnoush L, Salimi S, Shafiei M, Alavian SM. Liver Hemangioma Might Lead to overestimation of Liver Fibrosis by Fibroscan; A Missed Issue in Two Cases. Hepat Mon. 2012; 12(6): 408
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check